This course has been created to help healthcare professionals review the evidence supporting the role of alpelisib, a highly selective inhibitor of PI3K-alpha, for the treatment of advanced breast cancer.

It has been divided into four learning modules, each containing a ‘Key Opinions in Medicine’ article for you to read and an accompanying quiz to test your understanding.

You will receive a certificate on successful completion of the whole course.

Published: June 22, 2021

Take Course